{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T18:00:08Z","timestamp":1770487208577,"version":"3.49.0"},"reference-count":36,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,1,12]],"date-time":"2015-01-12T00:00:00Z","timestamp":1421020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Collegium Pharmaceutical"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pain Practice"],"published-print":{"date-parts":[[2016,3]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>Patients who have chronic pain with dysphagia (difficulty swallowing) (CPD<\/jats:styled-content>) often have difficulty taking oral medication and, as such, alter their medications by crushing or chewing in an attempt to make it easier to swallow. Such manipulation of currently marketed, extended\u2010release (ER<\/jats:styled-content>) opioid analgesics can significantly alter the pharmacokinetic (PK<\/jats:styled-content>) properties of the formulations, resulting in poor treatment outcome or serious adverse events. There is an unmet medical need for oral ER<\/jats:styled-content> opioid formulations suitable for patients with CPD<\/jats:styled-content>.<\/jats:p><\/jats:sec>Objective<\/jats:title>The primary objectives of this study were to conduct in vitro studies to evaluate alternate means of administration of a new, extended\u2010release (ER<\/jats:styled-content>), abuse\u2010deterrent, microsphere\u2010in\u2010capsule formulation of oxycodone for patients with CPD<\/jats:styled-content>. Specifically, these studies investigated the in vitro equivalence of drug release rates from Oxycodone DETER<\/jats:styled-content>x\u00ae<\/jats:sup> ER<\/jats:styled-content> intact capsules (control condition) and administration via alternate modes\u2014opening the capsule and sprinkling the microspheres onto soft foods or administration through enteral tubes. Secondary objectives were to compare alternate modes of administration of Oxycodone DETER<\/jats:styled-content>x\u00ae<\/jats:sup> to a commercially available ER<\/jats:styled-content>\u2010morphine product.<\/jats:p><\/jats:sec>Methods<\/jats:title>Soft food study: Oxycodone DETER<\/jats:styled-content>x\u00ae<\/jats:sup> microspheres were sprinkled onto and mixed with several soft foods (ie, applesauce, vanilla pudding, strawberry jam, yogurt, and vanilla ice cream); the effect of drug contact time (0, 30, and 60\u00a0minutes) on drug release was studied. Enteral tube study: Oxycodone DETER<\/jats:styled-content>x\u00ae<\/jats:sup> microspheres were administered through varying sizes of nasogastric (10 and 12 Fr.) tubes and a 16 Fr. gastrostomy tube using 5 different delivery vehicles (ie, water, liquid nutritional feeds [Jevity\u00ae<\/jats:sup>, Ensure\u00ae<\/jats:sup>], and milk [whole milk and 2% milk]). Drug release rate was characterized using a standard in vitro dissolution methodology; dissolution of intact Oxycodone DETER<\/jats:styled-content>x\u00ae<\/jats:sup> capsules served as the control for both the soft food and enteral tube studies. Oxycodone concentration was measured using a standardized high\u2010performance liquid chromatography (HPLC<\/jats:styled-content>) assay. Similarity factor (f2) analysis was used to compare similarity of the dissolution profiles of test and control conditions.<\/jats:p><\/jats:sec>Results<\/jats:title>The mean dissolution profile of Oxycodone DETER<\/jats:styled-content>x\u00ae<\/jats:sup> microspheres sprinkled onto and mixed with each of the soft foods were similar (f2\u00a0>\u00a050) to that of the control. Study drug\u2013food contact time did not impact dissolution profiles. The dissolution data obtained from Oxycodone DETER<\/jats:styled-content>x\u00ae<\/jats:sup> microspheres passed through enteral feeding tubes of varying sizes were similar (f2\u00a0>\u00a050) to that of the control. Unlike a marketed morphine sulfate ER<\/jats:styled-content> pellet formulation, Oxycodone DETER<\/jats:styled-content>x\u00ae<\/jats:sup> did not clog any of the studied enteral tubes.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>A new ER<\/jats:styled-content>, abuse\u2010deterrent, microsphere\u2010in\u2010capsule formulation of oxycodone can be administered by sprinkling onto soft food without affecting the drug release profile of the formulation. The formulation can also be administered directly via enteral tubes without affecting drug release and without clogging enteral tubes. Oxycodone DETER<\/jats:styled-content>x\u00ae<\/jats:sup> may offer physicians and patients with CPD<\/jats:styled-content> an alternate treatment option, especially in those patients who have dysphagia or an aversion to swallowing monolithic tablet\/capsule formulations and for whom analgesic patches or other opioid formulations are not a viable therapeutic option.<\/jats:p><\/jats:sec>","DOI":"10.1111\/papr.12280","type":"journal-article","created":{"date-parts":[[2015,1,12]],"date-time":"2015-01-12T12:21:38Z","timestamp":1421065298000},"page":"334-344","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of an Extended\u2010Release, Abuse\u2010Deterrent, Microsphere\u2010in\u2010Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD<\/scp>)"],"prefix":"10.1111","volume":"16","author":[{"given":"Alison B.","family":"Fleming","sequence":"first","affiliation":[{"name":"Collegium Pharmaceutical, Inc. Canton MA U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas R.","family":"Carlson","sequence":"additional","affiliation":[{"name":"Collegium Pharmaceutical, Inc. Canton MA U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi K.","family":"Varanasi","sequence":"additional","affiliation":[{"name":"Collegium Pharmaceutical, Inc. Canton MA U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Grima","sequence":"additional","affiliation":[{"name":"Collegium Pharmaceutical, Inc. Canton MA U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen P.","family":"Mayock","sequence":"additional","affiliation":[{"name":"Collegium Pharmaceutical, Inc. Canton MA U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Said","family":"Saim","sequence":"additional","affiliation":[{"name":"Collegium Pharmaceutical, Inc. Canton MA U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest A.","family":"Kopecky","sequence":"additional","affiliation":[{"name":"Collegium Pharmaceutical, Inc. Canton MA U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,1,12]]},"reference":[{"key":"e_1_2_8_2_1","volume-title":"Relieving Pain in America, A Blueprint for Transforming Prevention, Care, Education and Research","author":"Institute of Medicine Report from the Committee on Advancing Pain Research","year":"2011"},{"key":"e_1_2_8_3_1","unstructured":"The American Academy of Pain Medicine.AAPM Facts and Figures on Pain. 2013;http:\/\/www.painmed.org\/patientcenter\/facts_on_pain.aspx(accessed April 11 2013)."},{"key":"e_1_2_8_4_1","volume-title":"Voices of Chronic Pain: A National Study Conducted for American Pain Foundation","author":"American Pain Foundation","year":"2006"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2012.03.009"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jom.0000099999.27348.78"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S24170"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.PSY.0000106883.94059.C5"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.20.2433"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.psy.0000204851.15499.fc"},{"key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1176\/ps.2009.60.3.344","article-title":"Relationships among depression, chronic pain, chronic disabling pain, and medical costs","volume":"60","author":"Arnow BA","year":"2009","journal-title":"Psychiatr Serv."},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.20072"},{"key":"e_1_2_8_13_1","first-page":"269","article-title":"Current approach to dysphagia","volume":"5","author":"Gasiorowska A","year":"2009","journal-title":"Gastroenterol Hepatol."},{"key":"e_1_2_8_14_1","first-page":"3639","article-title":"Evaluating dysphagia","volume":"61","author":"Spieker MR","year":"2000","journal-title":"Am Fam Physician."},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000339974"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118321386.ch2"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2007.02.060045"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/000348940711601112"},{"key":"e_1_2_8_19_1","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research (CDER).Guidance for Industry: Size Shape and Other Physical Attributes of Generic Tablets and Capsules.http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM377938.pdf(accessed December 1 2013)."},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000016094"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2007.08.006"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.854197"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2005.05031.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ajp.0000210953.86255.8f"},{"key":"e_1_2_8_25_1","first-page":"12","article-title":"Medication errors in patients with dysphagia","volume":"108","author":"Kelly J","year":"2012","journal-title":"Nurs Times."},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2648.2011.05700.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00455-008-9170-3"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2648.2009.05145.x"},{"key":"e_1_2_8_29_1","unstructured":"Actavis Kadian LLC.KADIAN\u00ae(morphine sulfate) Extended\u2010Release Capsules for oral use CII: Prescribing Information.Morristown NJ:Actavis Kadian LLC;2012."},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.050176"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.1996.tb00015.x"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2014.0211"},{"key":"e_1_2_8_33_1","first-page":"64","article-title":"Mathematical comparison of curves with an emphasis on in vitro dissolution profiles","volume":"20","author":"Moore J","year":"1996","journal-title":"Pharm Tech."},{"key":"e_1_2_8_34_1","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research (CDER).Guidance for industry: SUPAC\u2010MR: modified release solid oral dosage forms. September 1997.http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm070640.pdf(accessed July 23 2013)."},{"key":"e_1_2_8_35_1","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research (CDER).Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms. 1997;http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070237.pdf(accessed June 30 2014)."},{"key":"e_1_2_8_36_1","article-title":"What is your gut feeling about opioid rotation?","author":"Didwaniya N","year":"2014","journal-title":"J Clin Oncol."},{"key":"e_1_2_8_37_1","volume-title":"AVINZA\u00ae (Morphine Sulfate Extended\u2010release Capsules) [Package Insert]","author":"Pfizer Inc","year":"2014"}],"container-title":["Pain Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpapr.12280","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/papr.12280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T15:04:45Z","timestamp":1696518285000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/papr.12280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,12]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1111\/papr.12280"],"URL":"https:\/\/doi.org\/10.1111\/papr.12280","archive":["Portico"],"relation":{},"ISSN":["1530-7085","1533-2500"],"issn-type":[{"value":"1530-7085","type":"print"},{"value":"1533-2500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,12]]}}}